The ROE as of September 2024 (TTM) for Cadrenal Therapeutics, Inc. Common Stock (CVKD) is -93.71%

According to Cadrenal Therapeutics, Inc. Common Stock’s latest financial reports and current stock price. The company's current ROE is -93.71%. This represents a change of 230.17% compared to the average of -28.38% of the last 4 quarters.

Cadrenal Therapeutics, Inc. Common Stock (CVKD) Historical ROE (quarterly & annually)

How has CVKD ROE performed in the past?

The mean historical ROE of Cadrenal Therapeutics, Inc. Common Stock over the last ten years is 6.16%. The current -93.71% ROE has changed -1622.12% with respect to the historical average. Over the past ten years (40 quarters), CVKD's ROE was at its highest in in the December 2022 quarter at 90.24%. The ROE was at its lowest in in the March 2023 quarter at -127.26%.

Cadrenal Therapeutics, Inc. Common Stock (CVKD) ROE by Quarter and Year

Discovering the peaks and valleys of Cadrenal Therapeutics, Inc. Common Stock ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Cadrenal Therapeutics, Inc. Common Stock (CVKD) Average ROE

How has CVKD ROE performed in the past?

The current ROE of Cadrenal Therapeutics, Inc. Common Stock (CVKD) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Cadrenal Therapeutics, Inc. Common Stock (CVKD) ROE vs. Peers

How is CVKD’s ROE compared to its peers?

Cadrenal Therapeutics, Inc. Common Stock’s ROE is greater than Mineralys Therapeutics, Inc. (-42.61%), greater than Structure Therapeutics Inc. (-20.15%), greater than Centessa Pharmaceuticals plc (-63.22%), greater than Nuvectis Pharma, Inc. (-152.26%), greater than Senti Biosciences, Inc. (-91.09%), less than ZIVO Bioscience, Inc. (673.84%), less than Foghorn Therapeutics Inc. (140.34%), greater than Quoin Pharmaceuticals, Ltd. (-112.11%), greater than Ikena Oncology, Inc. (-42.81%), greater than Enochian Biosciences, Inc. (-70.62%), greater than Eliem Therapeutics, Inc. (-47.03%), greater than HCW Biologics Inc. (-385.90%), greater than Exicure, Inc. (-288.03%), less than Cingulate Inc. (11.47%), greater than SAB Biotherapeutics, Inc. (-94.04%), greater than Anebulo Pharmaceuticals, Inc. (-122.97%), greater than Monopar Therapeutics Inc. (-110.60%), greater than AN2 Therapeutics, Inc. (-54.72%), greater than Miromatrix Medical Inc. (-119.21%), greater than Inhibikase Therapeutics, Inc. (-194.17%), greater than PMV Pharmaceuticals, Inc. (-21.96%),

Build a custom stock screener for Cadrenal Therapeutics, Inc. Common Stock (CVKD) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cadrenal Therapeutics, Inc. Common Stock using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cadrenal Therapeutics, Inc. Common Stock (CVKD) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cadrenal Therapeutics, Inc. Common Stock or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.